The B subunits of Shiga-like toxins induce regulated VWF secretion in a phospholipase D1-dependent manner.
Shiga toxin (Stx) causes diarrhea-associated hemolytic uremic syndrome by damaging renal microvascular endothelium. The pentameric B subunits of Stx types 1 and 2 (Stx1B and Stx2B) are sufficient to stimulate acute VWF secretion from endothelial cells, but Stx1B and Stx2B exert distinct effects on Ca(2+) and cAMP pathways. Therefore, we investigated other signaling components in StxB-induced VWF exocytosis. Incubation of HUVECs with StxB transiently increased phospholipase D (PLD) activity. Inhibition of PLD activity or shRNA-mediated PLD1 knockdown abolished StxB-induced VWF secretion. In addition, treatment with StxB triggered actin polymerization, enhanced endothelial monolayer permeability, and activated RhoA. PLD activation and VWF secretion induced by Stx1B were abolished on protein kinase Cα (PKCα) inhibition or gene silencing but were only moderately reduced by Rho or Rho kinase inhibitors. Conversely, PLD activation and VWF exocytosis induced by Stx2B were reduced by Rho/Rho kinase inhibitors and dominant-negative RhoA, whereas attenuation of PKCα did not affect either process. Another PLD1 activator, ADP-ribosylation factor 6, was involved in VWF secretion induced by Stx1B or Stx2B, but not histamine. These data indicate that Stx1B and Stx2B induce acute VWF secretion in a PLD1-dependent manner but do so by differentially modulating PKCα, RhoA, and ADP-ribosylation factor 6.
Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA.
Jing
J
Huang
Sandra L
SL
Haberichter
J Evan
JE
Sadler
D000089982:ADP-Ribosylation Factor 6; D020727:ADP-Ribosylation Factors / Q000378:metabolism; D008841:Actin Cytoskeleton / Q000187:drug effects / Q000378:metabolism; D002478:Cells, Cultured; D004353:Drug Evaluation, Preclinical; D004789:Enzyme Activation / Q000187:drug effects / Q000502:physiology; D061307:Human Umbilical Vein Endothelial Cells / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D006801:Humans; D010539:Permeability / Q000187:drug effects; D010739:Phospholipase D / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D051571:Protein Kinase C-alpha / Q000378:metabolism; D021122:Protein Subunits / Q000378:metabolism / Q000494:pharmacology; D034741:RNA, Small Interfering / Q000494:pharmacology; D022641:Shiga Toxin 2 / Q000494:pharmacology; D022603:Shiga Toxins / Q000737:chemistry / Q000494:pharmacology*; D013997:Time Factors; D020742:rhoA GTP-Binding Protein / Q000378:metabolism; D014841:von Willebrand Factor / Q000378:metabolism*
D000089982:ADP-Ribosylation Factor 6; D021122:Protein Subunits; D034741:RNA, Small Interfering; D022641:Shiga Toxin 2; D022603:Shiga Toxins; C450841:shiga toxin 2 B subunit; D014841:von Willebrand Factor; D051571:Protein Kinase C-alpha; D010739:Phospholipase D; C106801:phospholipase D1; D020727:ADP-Ribosylation Factors; C000715348:ARF6 protein, human; D020742:rhoA GTP-Binding Protein